Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,016 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% sodium chloride solution Clear all
Recruiting Phase 1Phase 2 Interventional

Intranasal Insulin for Treatment of Alcohol Use Disorder

NCT05988632
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth

NCT02224625
View directory record Official record
Conditions
Surgery
Interventions
2% CHG Cloth solution, Vehicle Cloth, Active Comparator, Saline, SLS
Drug · Device · Other
Lead sponsor
Medline Industries
Industry
Eligibility
16 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 15, 2026, 2:38 PM EDT
Not listed Early Phase 1 Interventional

Spinal Fusions Steroid Study

NCT05287035
View directory record Official record
Conditions
Spinal Fusion
Interventions
Dexamethasone injection, Saline injection
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
10 Years to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Consciousness, Psilocybin, and Well-Being

NCT05592379
View directory record Official record
Conditions
Healthy, Psychedelic Experiences, Sleep
Interventions
Psilocybin, Clonidine, Saline
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Not applicable Interventional Results available

Analgesic Value of Adductor Canal vs Femoral Block After Total Knee Arthroplasty

NCT03395990
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Active comparator: chloroprocaine, Sham comparator: saline
Procedure
Lead sponsor
Duke University
Other
Eligibility
56 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 15, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

Antibiotic Tumescent For Chronic Wounds

NCT06327113
View directory record Official record
Conditions
Non-healing Wound
Interventions
CeFAZolin Injectable Solution
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 15, 2026, 2:38 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Intravenous Tranexamic Acid During Rhytidectomy

NCT03970213
View directory record Official record
Conditions
Bleeding, Bruising Face, Swelling Lips & Face
Interventions
Tranexamic Acid 100Mg/Ml Inj Vil 10Ml, Normal Saline 0.9% Infusion Solution Bag
Drug
Lead sponsor
Glasgold Group Plastic Surgery
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 15, 2026, 2:38 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

NCT06253923
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Amantadine Hydrochloride, Placebo
Drug
Lead sponsor
SHINKEI Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

NCT00105183
View directory record Official record
Conditions
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions
Placebo, EZ-2053, EZ-2053 5mg/kg
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 15, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional

H. Pylori Eradication With Argon Plasma During Endoscopy

NCT06529159
View directory record Official record
Conditions
Helicobacter Pylori Infection, Helicobacter Pylori, Helicobacter Pylori Gastrointestinal Tract Infection, H. Pylori Infection, H. Pylori Gastrointestinal Disease
Interventions
HEAPE, Pre-HEAPE
Procedure
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

NCT04589403
View directory record Official record
Conditions
Healthy
Interventions
OPT101
Drug
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Stellate Ganglion Blockade in Post-Menopausal Women

NCT02907983
View directory record Official record
Conditions
Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions
Stellate Ganglion Block Injection with Bupivicaine, Saline injection
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Immunomodulatory Properties of Ketamine in Sepsis

NCT01089361
View directory record Official record
Conditions
Sepsis
Interventions
Ketamine, Normal Saline placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 15, 2026, 2:38 PM EDT
Recruiting Phase 1 Interventional

Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

NCT07253662
View directory record Official record
Conditions
Adenocarcinoma Pancreas
Interventions
PIPAC, Nab-paclitaxel
Device · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran Injection, Placebo
Drug · Other
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 4 Interventional

7% Hypertonic Saline for Acute Bronchiolitis

NCT01871857
View directory record Official record
Conditions
Acute Bronchiolitis
Interventions
Hypertonic saline and epinephrine, Normal saline and epinephrine
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
6 Weeks to 2 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 15, 2026, 2:38 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) Trial

NCT07215000
View directory record Official record
Conditions
Colorectal Cancer Screening, Bowel Cleansing for Colonoscopy
Interventions
Golytely, Sulfave, Sutab
Drug
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

NCT02770807
View directory record Official record
Conditions
Nervous System Disease, Genetic Syndrome
Interventions
EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
View directory record Official record
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis

NCT02799472
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165, Placebo, MTX, Folic (or folinic) acid
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 15, 2026, 2:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Influence of Osmotic Stimulation of Vasopressin on Autonomic Function

NCT04233606
View directory record Official record
Conditions
Water Stress, Body Water Dehydration
Interventions
Hypertonic Saline, Normal Saline
Other
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Neo-Synalar Modified 48 Hour Patch Test

NCT02168478
View directory record Official record
Conditions
Allergy
Interventions
Neo-Synalar Cream, Sodium Lauryl Sulfate Aqueous Solution (0.40%), Saline
Drug · Other
Lead sponsor
Noah Rosenberg, MD
Industry
Eligibility
18 Years to 79 Years
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain

NCT03848143
View directory record Official record
Conditions
Neuropathic Pain
Interventions
onabotulinum toxin A
Drug
Lead sponsor
Isabel Moreno Hay
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 15, 2026, 2:38 PM EDT